Sign in
Taking peopleNo phase

Immune cells and gut bacteria in people with idiopathic nephrotic syndrome

Measures blood immune cells and gut bacteria in people with idiopathic nephrotic syndrome.

Key facts

Who runs it
Nantes University Hospital
Where
France2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
INS, B Cells and Microbiota
Status
Recruiting
People taking part
30 people, planned
Started
18 Jan 2022
Expected to end
18 Jan 2027
Type of study
Observational, 2 groups
Treatments tested
  • Measurement of blood immune populations and microbiota distribution.
Record updated
3 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with a flare of nephrotic syndrome, a kidney condition that makes the body lose protein in the urine. It compares idiopathic nephrotic syndrome (no known cause) with other kidney diseases of this type. It studies blood immune cells and gut bacteria.

Age
12 years and older
Sex
All sexes
Disease stage
In a nephrotic flare: urine protein above 3g per 24h, or a urine protein/creatinine ratio above 3, or as judged by the doctor. Main group: idiopathic nephrotic syndrome. A smaller group has nephrotic syndrome from IgA, GEM type or another kidney filter disease.
Earlier treatment
People cannot join if they take immunosuppressants or corticosteroids above 10 mg/d.
Biomarker or test result
Urine protein above 3g per 24h, or urine protein/creatinine ratio above 3, unless the doctor decides otherwise.

Main reasons for not taking part

  • Past flares that did not respond to corticosteroid treatment
  • Weight under 50 kg (110 lb)
  • Pregnant women
  • People under guardianship or curatorship
  • Current immunosuppressant treatment or corticosteroids above 10 mg/d

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patient treated in participating centers
  • In nephrotic attack, defined biologically by:; Proteinuria > 3g 24h or A proteinuria/creatinuria ratio > 3 or Defined at the discretion of the clinician; Non inclusion Criteria :
  • Patient with a history of NIS flare-ups resistant to corticosteroid therapy
  • Patient treated with immunosuppressant
  • Patient treated with corticosteroids > 10 mg/d
  • Weight <50 kg
  • Pregnant woman
  • Patient under guardianship / curatorship

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Idiopathic nephrotic syndrome (NIS) is a clinical entity defined by the association of selective albuminuria, hypoalbuminemia, and nonspecific glomerular lesions (lesions minimal glomerular (LGM) or segmental and focal hyalinosis (HSF). The complication of this kidney disease is the progression towards chronic renal failure and in case of kidney transplantation, its immediate recurrence on the graft . The origin of this syndrome is unknown but a number of clinical observations tend to show an involvement of immune system. A link has been highlighted between atopy, diet and nephrotic flare-ups. The speed of recurrence of this initial disease on the graft and the observation of remissions obtained after treatment by plasma exchange or immunoadsorptions support the presence of a pathogenic plasma factor. Anti-CD20 treatments depleting B lymphocytes has made it possible to favorably treat a number of patients. Dysfunction of regulatory T cells has also been shown in SNI patients. This modification seems linked to allergies and could be due to an aberrant microbiota. The hypothesis of causality between dysbiosis, alteration lymphocyte and triggering of an SNI was mentioned recently. Two studies have shown intestinal dysbiosis in pediatric SNI/LGM, with reduction of T circulating regulators

The 2 groups in the trial

  • Patient with nephrotic syndrome idiopathic

    nephrotic INS patients in primary visit: harvesting of 27.5 ml supplementary blood, 40 mlurine and feces at inclusion visit and at 3 months. No intervention, no treatment administration other than usual/routine INS treatment.

    Treatment: Measurement of blood immune populations and microbiota distribution.

  • Patient with nephrotic syndrome no idiopathic, IgA or GEM type or other glomerulopathy

    At least 10 NS no idipathic patients: harvesting of 27.5 ml supplementary blood, 40 ml urine and feces at inclusion visit and at 3 months. No intervention, no treatment administration other than usual/routine care treatment.

    Treatment: Measurement of blood immune populations and microbiota distribution.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Controlled Multicenter Epidemiological Study of Peripheral Leukocyte Populations and Microbiota in Patients With Idiopathic Nephrotic Syndrome (INS)
Plain-language title
Immune cells and gut bacteria in people with idiopathic nephrotic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
3 March 2026